文献速递认知障碍与痴呆

亚阈值淀粉样蛋白及其生物学与临床意义:前路漫长

Subthreshold amyloid and its biological and clinical meaning: Long way ahead.
PubMed 文献 · Neurology · 2019-06-05

本文整合β-淀粉样蛋白(Aβ)组织病理学与在体Aβ影像的文献,提出重新审视阈值以下Aβ沉积的临床价值。近期证据提示,低于Aβ阳性阈值的在体Aβ沉积可预示未来认知下降与AD病理累积,且可能始于较年轻年龄。作者倡导研究早期Aβ积累速率、促进因素、不同Aβ标记比较及纵向设计,以阐明AD病理从良性向恶性阶段的转变,为疾病修饰干预提供新窗口。

要点

  • 低于Aβ阳性阈值的在体Aβ沉积可预示未来认知下降与AD病理累积。
  • 亚阈值Aβ积累可能已在较年轻年龄发生,需关注早期积累速率及促进因素。
  • 需纵向设计及不同Aβ标记比较,以明确AD病理从良性向恶性转变的节点。

核心结论

  • 亚阈值Aβ沉积携带未来认知下降与AD病理累积的关键信息,需重新概念化其临床意义。

研究设计与样本

  • 整合现有Aβ组织病理学与在体Aβ影像文献的叙述性综述。

主要发现

  • 在体Aβ沉积低于Aβ阳性阈值时,仍可预示未来认知下降与AD病理累积,且可能始于较年轻年龄。

临床怎么用

  • 建议关注早期Aβ积累速率及促进因素,并开展不同Aβ标记的比较研究与纵向设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The development of in vivo imaging of the pathologic hallmark of Alzheimer disease (AD), β-amyloid (Aβ), altered the framing of its pathophysiology and formulation of inclusion criteria for clinical trials. Recent evidence suggests that in vivo measures of Aβ deposition below a threshold indicative of Aβ positivity carry critical information on future cognitive decline and accumulation of AD pathology, potentially already at a younger age. Here, we integrate the existing literature on histopathology of Aβ and its convergence and divergence with in vivo Aβ imaging. The evidence presented amounts to a reconceptualization, in which we advocate for a closer look into Aβ accumulation rates in earlier life, the factors that promote accumulation, comparative studies with different markers of Aβ, and longitudinal designs to elucidate when AD pathology rises and how it shifts from benign to malignant stages that ultimately define AD. These efforts open a new window of opportunity for disease-modifying interventions.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Bischof GN, Jacobs HIL. Subthreshold amyloid and its biological and clinical meaning: Long way ahead. Neurology. 2019. PMID: 31167933. doi:10.1212/WNL.0000000000007747

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。